Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D-HDRA Guided TACE in Primary Liver Cancer
NCT05701436Phase 3Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, doxorubicin, lobaplatin, cisplatin, fluorouracil in hepatocellular carcinoma (HCC), sponsored by Southern Medical University Zhujiang Hospital. Started Sep 2022; status: recruiting.
02
Drugs
oxaliplatindoxorubicinlobaplatincisplatinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05701436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701436.